Drugs

Jenny Seligmann: FOxTROT 5 Opens in the UK – New immunotherapy trial for older colon cancer patients

Jenny Seligmann/yorkshirecancerresearch.org.uk

May 9, 2025, 07:19

Jenny Seligmann: FOxTROT 5 Opens in the UK – New immunotherapy trial for older colon cancer patients

Jenny Seligmann, Professor of Gastrointestinal Oncology at the University of Leeds, shared a post by Research and Innovation Department at Leeds Teaching Hospitals NHS Trust, on LinkedIn, adding:

“FOxTROT 5 now open and already 9 patients recruited! Thanks to Campbell Roxburgh and the team at CTRU Leeds and GSK.

Let’s create an evidence base for treating older pts with immunotherapy too!
…watch this space for news on FOxTROT 6.”

Quoting Research and Innovation Department at Leeds Teaching Hospitals NHS Trust‘s post:

“New immunotherapy trial for older colon cancer patients launches in Leeds

We are proud to support FOxTROT 5 – a groundbreaking clinical trial led by the University of Leeds and supported by the NIHR Leeds Clinical Research Facility.

The trial is focused on older or frail patients with a specific type of colon cancer (dMMR). Instead of the standard approach – surgery first, then chemotherapy – participants will receive immunotherapy (dostarlimab) before surgery.

The study run across 20 UK hospitals aims to reduce health inequality and personalise cancer care for a vulnerable population.

Professor Jenny Seligmann, Consultant Medical Oncologist and FOxTROT 5 Chief Investigator, said:

“This approach has already shown promise in younger patients, but we lack the evidence to guide treatment for older patients. FOxTROT 5 aims to change that.”

The trial is funded by GSK and is part of the broader FOxTROT platform, supported by Yorkshire Cancer Research and several leading UK universities.

To learn more or get involved.”

More posts featuring Colon Cancer on OncoDaily.